Website Update 2011

John-Michael Maas

Information is everywhere.

Where is the information?

The information is in all of you.


NEW WEBSITE
Podcasts
Videos
Meeting Recaps
Expanded Blog
TARGETS DATABASE
RESOURCE CATALOG
Biologics
Discovery
Drug Pipeline
EXPANDED PIPELINE
GRANTS FINDER
CLINICAL TRIALS DATABASE
ROBUST COMMUNITY

Evolving to an information sharing platform

Blog feed on the homepage
Video / Podcast promotion
Messages to members
Get involved
Social media

Whole site has been redesigned with further rollouts through Q1 2012.



up from 145 last year

PERIOD: YTD



ANALYTICS

Strong user growth

- Sustained audience (peaks with communications)
- Audience growth
- Positive response to site enhancements
- Rising search traffic (58% last month)
- Time on site remains strong (4:00 since launch of new site)

PIPELINE

Login/Register to add a Project

Download the PPT Slide

CLINICAL DEVELOPMENT

PRECLINICAL DEVELOPMENT

CPZEN-45
Caprazene nucleoside
Microbial Chemistry Research Foundation, Tokyo, Japan, Lilly TB Drug Discovery Initiative, NIAID, IDRI, Lilly, YourEncore

Quinolone DC-159a
Fluoroquinolone Antibiotics
Japan Anti-Tuberculosis Association, JATA, Daiichi-Sankyo Pharmaceutical Co.

SQ609
Dipiperidines
Sequella

SQ641
Capuramycins
Sequella

BTZ043 GLP
Benzothiazinones
New Medicines For Tuberculosis (NM4TB)

Q201-Novel anti-TB agent
Imidazopyridine
Quro Science, Inc.

PHASE I

AZD5847 NCE
Oxazolidinone
Astrazeneca

PHASE II

PA-824 REG NCE
Nitroimidazol-oxazine
TB Alliance

Novel Combinations/Regimens NCE
Nitroimidazol-oxazine, diarylquinoline, fluoroquinolone, Nicotinic acid derivative
TB Alliance

PNU-100480 NCE
Oxazolidinone
Pfizer

TMC207 (Bedaquiline) for MDR-TB NCE
Diarylquinoline
Tibotec BVBA

SQ109 NCE
Ethylenediamines
Sequella,NIH

TMC207(Bedaquiline) for DS-TB NCE
Diarylquinoline
TB Alliance, Janssen Pharmaceutica N.V.

OPC-67683 (Delamanid) NCE
Nitro-dihydro-imidazooxazole
Otsuka Pharmaceutical Co., Ltd.

Linezolid for MDR-TB
Oxazolidinones
TBTC, Pfizer

Rifapentine (TBTC study 29)
Rifamycin
CDC, Sanofi-aventis

PHASE III

Gatifloxacin
Fluoroquinolones
Information provided by WGND

Moxifloxacin for Drug-Sensitive TB
Fluoroquinolones
University College London

Rifapentine (TBTC Study 26)
Rifamycin
CDC, Sanofi-aventis

The Pipeline – Pre/Clinical

No drop outs
2 advanced to Phase II
1 advanced to Phase III

2010		2011
18	➡	**19**
compounds		compounds

DISCOVERY PIPELINE

Login/Register to add a Project

Download the PPT Slide

HIT-TO-LEAD

Phenotypic Hit-to-Lead
University of Illinois, TB Alliance

M. tuberculosis Protein Kinase Inhibitors
Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles
Vertex Pharmaceuticals, Incorporated

Fungal metabolites
Mycosynthetix, University of Illinois at Chicago

Actinomycete metabolites
University of Illinois at Chicago, Myongji University

DNA metabolism
Novel structural class
AstraZeneca R and D Bangalore

Phenotypic hit to lead
Multiple novel structural classes
Lilly TB Drug Discovery Initiative

Novel hit-lead programs
Novel structural class
Lilly TB Drug Discovery Initative

Phenotype Hit-to-Lead
Novel structural classes
AstraZeneca R and D Bangalore

Combinatorial Biosynthetic Compounds
Shaw Environmental and University of Illinois at Chicago

Folate Biosynthesis Inhibitors
AstraZeneca, TB Alliance

Phenotypic Hit-to-Lead
GlaxoSmithKline, TB Alliance

Malate Synthase Inhibitors
GlaxoSmithKline , Texas A&M University, TB Alliance

Menaquinone Synthase Inhibitors
Colorado State University, TB Alliance

Inhibitors of Mycobacterium Tuberculosis Energy Metabolism
Various Classes
UPenn and TB Alliance

Inhibitors of isoprenoid biosynthesis
Lilly TB Drug Discovery Initiative

Protein Splicing Inhibitors
Boston Biomedical Research Institute

LEAD-OPTIMIZATION

Nitroimidazoles
Nitroimidazoles
TB Alliance, University of Auckland, University of Illinois

Diarylquinolines
Diarylquinoline
TB Alliance, University of Auckland, Tibotec

Riminophenazines
Riminophenazines antibiotic
TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois

InhA Inhibitors
Novel structural class
GlaxoSmithKline, TB Alliance

LeuRS inhibitors
Oxaboroles
Anacor Pharmaceuticals

Mycobacterial Gyrase Inhibitors
Novel structural class
TB Alliance, GlaxoSmithKline

Pyrazinamide Analogs
Pyrazinamide/nicotinamide analogs
TB Alliance/Yonsei University

TL1 Inhibitors
Capuramycins
Sequella

MTopo
Novel structural class
AstraZeneca R and D Bangalore

GyrB Inhibitors
AstraZeneca , TB Alliance

SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis
Inorganic Compounds
FAPESP/Brazil

Spectinamides
Spectinomycin analogs
St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix



The Pipeline – Discovery

No drop outs
4 new hit-to-lead
3 new lead-optimization

2010	2011
21	**28**
compounds	compounds

Coming Soon: WGND Clinical Trials Database

newtbdrugs.org/clinical

WORKING GROUP ON NEW TB DRUGS

Critical Path to TB Drug Regimens

Four main components:

- Registration Clinical Trial Sites
- Other TB Clinical Trial Sites
- New Concepts
- List of TB Drug Trials



New Resource:
CLINICAL TRIALS » REGISTRATION CLINICAL TRIAL SITES

Status:
Built
Integrating data
(complete Q4 2011)

Development partners:
Andrew Vernon / CDC,
Barbara Laughon / NIH/NIAID
and CPTR



Filtering results:



Click a site name to view details:

WORKING GROUP ON NEW TB DRUGS

Stop TB Partnership

Blog | Pipeline | Clinical Research | Resources | Meetings | About Us

Overview | Core Group | Subgroups | Members | Contact Us

CLINICAL TRIALS » REGISTRATION READY SITES

Submit a Site to the Database

« Return to Registration Ready Sites Overview

Shanghai Pulmonary Hospital (Shanghai, China)

Last Updated: 11-Nov-2010

SITE INFORMATION

Address:
No. 507 Zhengmin Road
Yangpu District
Shanghai, China
» view their website

Site Leader:
Dr. Heping Xiao
» email

Community / Advocacy Contact:
Zhang Min
» email

SITE PARTICULARS

Number of patients enrolled in a registration quality trial over the last 24 months: **100**
Certified lab with MGIT & LJ culture: **Yes**

Patients Available

Pediatric	MDR	HIV/TB
Yes	Yes	Yes

Clinical Trials Experience

TRIAL NAME	NETWORK / CTU / PI	# PATIENTS	SPONSOR	SPONSOR CONTACT	NCT#	OTHER REGISTRATION LINKS
C-001-402	Info goes here	600	Sponsor Name	Contact Name » email	NCT00398931	WHO6789
C-001-403	Info goes here	600	Sponsor Name	Contact Name » email	NCT00398931	WHO6789

External Reference Links
TB Alliance Site Eval Link
TBTC Site Eval Link

Related Links and Publications
Publication Number One
Another Pub

Downloads
Download Name Link
Another Download Name Link

ADDITIONAL COMMENTS

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam. Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate. Praesent adipiscing elementum tincidunt. Donec ultrices lacinia dictum. Suspendisse gravida, lorem id fermentum consectetur, urna mi vehicula tellus, consequat suscipit velit nisi id massa. In faucibus, dolor vel vestibulum lobortis, sem metus tincidunt odio, nec viverra tortor sapien et eros.

Site by Darby Communications

About | Contact Us | Privacy policy

The Working Group is Supported By Stop TB Partnership



New Resource:
CLINICAL TRIALS »
NEW CONCEPTS

Status:
Design complete
Under construction (Q1 2012)

Development partners:
Andrew Vernon / CDC &
Barbara Laughon / NIH/NIAID
and CPTR



New Resource:
CLINICAL TRIALS »
TB DRUG TRIALS

Status:
Design complete
Assembling data
Under construction (Q1 2012)

Development partners:
Andrew Vernon / CDC,
Barbara Laughon / NIH/NIAID
and CPTR

Additional Site Enhancements

Delivering in Q4 2011 and Q1 2012



New Resource:

Targets

Status:
Currently built
In the process of integrating data
Launch Q4 2011

Development partner:
Christopher Locher / Vertex

Click to view target details:

Explore. Learn. Join the conversation. Follow us on:

WORKING GROUP ON NEW TB DRUGS

Stop TB Partnership

Blog | Pipeline | About Us | Meetings | TB Resources

Discovery Pipeline | Pipeline | Add a Project | View Previous Pipelines | Register/Login to Pipeline

TARGETS

Edit Target

Return to Targets Overview

GSK / TB Alliance Tres Cantos

Last Updated: 11-Nov-2010

CONTACT INFO
Jose-Luis Lavandera
jose-luis.d.lavandera@gsk.com
1-124-125-6789

TARGET DESCRIPTION

Name
isocitrate lyase

EC number	Genbank accession	Rv number
4.1.3.1	CAE55284.1	Rv0467

HAS THE TARGET BEEN VALIDATED? HOW?

Validated by
Genetically (in vitro or in vivo)

PubMed References
PMIDs or citations

Reagent Description

RECOMBINANT PROTEIN NAME / GENE ID	SOLUBLE?	FORMAT	PubMed REFERENCES
Rv0467-Sc013	Yes	November 2009	Completed

Assay Description (Target or Cell Based)

ASSAY NAME	READOUT	FORMAT	PubMed REFERENCES
My-isocitrate-lyase-assay	Fluorescence	November 2009	Completed
My Mtb cell phenotypic screen	Absorbance	Petri dish	PMIDs or citations

Compounds for Screening or Lead Optimization

LIBRARY NAME/IDENTIFIER	TOTAL # OF COMPOUNDS	SCREENED	HTS CUT OFF (ie. 40 um)	# OF HITS	# OF LEADS	PubMed REFERENCES
GSK Library	500,000	10000	40 um	10	0	PMIDs or citations
Rational design/fragment-based screening	50	40	40 um	3	1	PMIDs or citations

HITS OR LEADS

Chemical Class
Riminophenazines

COUNTER-SCREEN ASSAY (Target or Cell Based)

Mammalian enzyme
E. coli or other species

NARRATIVE DESCRIPTION

No tractable hits emerged from enzymatic HTS against Icl1 and Icl2. High background of unannotated oxalate (Icl inhibitor) salts in commercial compounds

Site by Darby Communications

About | Contact Us | Privacy policy

The Working Group is Supported By Stop TB Partnership



New Resource:
BIOLOGICS

Status:
Design complete
Under construction
Launch (Q1 2012)

Development partner:
Christopher Locher / Vertex

Click to view biologics details:

Explore. Learn. Join the conversation. Follow us on:

WORKING GROUP ON NEW TB DRUGS

Stop TB Partnership

Blog | Pipeline | About Us | Meetings | TB Resources

Discovery Pipeline | Pipeline | Add a Project | View Previous Pipelines | Register/Login to Pipeline

PIPELINE > BIOLOGICS

Add a Compound to Biologics Database | Download Biologics Database

Product/Compound Name

Last Updated: 11-Nov-2010

PRODUCT PROFILE

Potential
Will be inexpensive, scaleable, available for pro-duction. This text could go on to a second line or more as needed.

Potential Biomarkers
Decreased IL-4, decreased TNF-alpha. This text could go on to a second line or more as needed.

Therapeutic Goal
Clinical improvement / survival, STSC

Initial Target Population
+/- MDR, +/- HIV

CONCERNS AND RECOMMENDATIONS

Toxicity
NK (cardiotoxicity for COX2 inhibitors).

Next Step
Complete GMP production.

Additional Description
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper

CONTACT INFO
Jose-Luis Lavandera
jose-luis.d.lavandera@gsk.com
1-124-125-6789

EVALUATIONS
Preclinical Tax: Not completed
Phase I Safety: not established
Phase I/II preliminary efficacy: yes

ADMINISTRATION AND HANDLING

DOSE	ROUTE	SCHEDULES	COLD CHAIN	STORAGE
1mg	Oral Dosing	Multiple 5 daily doses every six weeks.	Yes	>1 yr at +4ºC and 3 months

RELATED LINKS

This is the first link text.
This is another link.
This is yet another related link to this particular product or compound.

Download the WHO Report

Site by Darby Communications

About | Contact Us | Privacy policy

The Working Group is Supported By Stop TB Partnership

New Resource:
MEETING RECAPS

Launched with
PZA Workshop
(DC / May 31 – June 1)

Features:
- presentations
- video presentations
- agenda
- speakers / attendees



View Synopsis | Download Presentation [608kb]

Click to play

New aspects of the activity of PZA
John Welch
Download Presentation [10,200kb]

Click to play

Does pyrazinamide have a host-directed mechanism of action?
Nicole Ammerman
View Synopsis | Download Presentation [680kb]

Click to play

SESSION 2

Pyrazinamide treatment prevents the clinical signs of cutaneous leishmaniasis
Susana Mendez
View Synopsis | Download Presentation [6,300kb]

Click to play

What do we know about the intracellular environment experienced by *M. tuberculosis*?
David Russell
View Synopsis | Download Presentation [18,900kb]

Click to play

***nad* biosynthetic mutants of *Mycobacterium tuberculosis*: a tool to elucidate PZA action**
Catherine Vilcheze & William Jacobs
View Synopsis | Download Presentation [1,200kb]

Click to play

SESSION 3

In search of parsimony: An alternative hypothesis for the mode of action of pyrazinamide
Anthony Baughn
View Synopsis | Download Presentation [764kb]

Click to play

Pyrazinamide, sterilizing drug only?
Jacques Grosset
View Synopsis | Download Presentation [140kb]

Click to play

Efficacy of PZA administered as a single drug in various TB mouse infection models (GKO, Balb/c and Kramnik)
Anne Lenaerts
Download Presentation [13,400kb]

Click to play

SESSION 4

The Roller Coaster of PZA
Ying Zhang
View Synopsis | Download Presentation [5,700kb]

Click to play

Discovery of a new generation pyrazinamide
Zhenkun Ma
View Synopsis | Download Presentation [1,200kb]

Click to play

NEXT STEPS

Overview of Planned NIH Sponsored PZA Workshop scheduled for Spring 2012
Richard Hafner
View Synopsis

Boshoff, Helena
Tuberculosis Research Section, LCID, NIAID, NIH, DHHS

Deininger, David
Vertex Pharmaceuticals Incorporated

Farhat, Maha
Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital

Grosset, Jacques
Center for Tuberculosis Research
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine

Hafner, Richard
Division of AIDS, NIAID, NIH, DHHS

Jacobs, William
Department of Microbiology & Immunology
Albert Einstein College of Medicine
Michael F. Price Center

Lacourciere, Karen
Respiratory Disease Branch, NIAID, NIH, DHHS

Laughon, Barbara
Division of Microbiology and Infectious Diseases, NIAID, NIH

Lenaerts, Anne
Department of Microbiology, Immunology and Pathology
Colorado State University

Locher, Christopher
Vertex Pharmaceuticals Incorporated

Ma, Zhenkun
TB Alliance

Makhene, Mamodikoe
Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS

Mendez, Susana
Baker Institute for Animal Health
Cornell University

Nuermberger, Eric
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine

Russell, David
Microbiology and Immunology
College of Veterinary Medicine
Cornell University

Scott, Cherise
Working Group on New TB Drugs

Sizemore, Christine
Respiratory Disease Branch, NIAID, NIH, DHHS

Spigelman, Mel
TB Alliance

Vilcheze, Catherine
Department of Microbiology & Immunology
Albert Einstein College of Medicine

Welch, John
Chemistry
College of Arts and Sciences
University of Albany

Zhang, Ying
Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health

Zimhony, Oren
Division of Infectious Diseases
Kaplan Medical Center Rehovot
Hebrew University and Hadassah

Site by Darby Communications

About | Contact Us

The Working Group is Supported by Stop TB Partnership

New Resource:
MEETING RECAPS

COMPREHENSIVE!



Enhanced Resource:
TB RESOURCE CATALOG

Status:
Fully operational
Integrating Data (Q4 2011)

Development partner:
Gerhard Walzl / Stellenboch

Enhanced Resource:
TB GRANTS FINDER

Status:
Fully operational

Looking for partners to help populate with fresh data

Will be adding a form to submit grants data

WORKING GROUP
ON NEW TB DRUGS

Explore. Learn.

Join the conversation.